Carl-Emil Lim

7PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersCardiology (incl. cardiovascular diseases)PharmacogenomicsExercise physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 05, 2026
Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

|Mar 11, 2026
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.

Tessa H Reitsma, Carl-Emil Lim, Mari N Gynnild

|Feb 09, 2026
Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score.

Joris Holtrop, Mari N Gynnild, Matthew Richards

|Nov 04, 2025
Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.

Ali Yari, Carl-Emil Lim, Emil Hagström

|May 02, 2025
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.

Carl-Emil Lim, Björn Pasternak, Björn Eliasson

|Dec 30, 2022
Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.

Carl-Emil Lim, Björn Pasternak, Björn Eliasson

Pageof 2

Frequent Collaborators

6 joint publications

Peter Ueda

4 joint publications

Tomas Jernberg

3 joint publications

Deepak L Bhatt

3 joint publications

Salil V Deo